Global named patient use (NPU) program of afatinib in heavily pretreated advanced NSCLC patients who progressed following prior therapies, including erlotinib or gefitinib. (February 2017) - Hochmair, M.; Cappuzzo, F.; Tsai, C.M.; Schuler, M.; Lam, K.C.; Stehle, G.; Cseh, A.; Lorence, R.M.; Linden, S.; Carrière, P.; Soo, R.